Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Immunotherapy: A New Frontier for Anti-tumor"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 3001
Special Issue Editors
Interests: DNA damage; immunotherapy; pre-mRNA alternative splicing
Special Issue Information
Immunotherapies that harness or enhance a patient’s own immune system to target and kill cancer cells have been very successful for certain types of advanced cancers, such as lung, bladder, and skin cancer. The major therapeutic approaches are the use of antibodies against inhibitory signaling molecules expressed on tumor and immune cells. Although immune checkpoint blockade agents are very promising, only a small subset of patients respond to these agents, and there is increased evidence of primary and adaptive resistance to immune checkpoint blockade in multiple cancer types. Therefore, these is an urgent need to identify novel anti-tumor therapeutic approaches and understand mechanisms of anti-tumor immunotherapeutic.
This Special Issue aims to gather the frontier of anti-tumor immunotherapy strategies to provide new avenues for developing next-generation immunotherapies. In this Special Issue, original research articles case reports, reviews and mini reviews are welcome. Research areas may include (but not limited to) the following:
- Novel approaches to cancer immunotherapy
- Immunological assessment of tumor microenvironment
- Mechanisms of novel anti-tumor immunotherapies
- Cancer vaccines
- Combination of immunotherapy with targeted therapy
- Advanced tools to analyze and integrate immune repertoire data.
We look forward to receiving your contributions.
Dr. Jing Zhang
Dr. Qinqin Pu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.